Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience

BACKGROUND: Immunotherapy is emerging as the cornerstone for treatment of patients with advanced cancer, but significant toxicity (immune-related adverse events [irAEs]) associated with unbridled T cell activity remains a concern. PATIENTS AND METHODS: A retrospective review of the electronic medica...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Invest New Drugs
Asıl Yazarlar: Fujii, Takeo, Colen, Rivka R., Bilen, Mehmet Asim, Hess, Kenneth R., Hajjar, Joud, Suarez-Almazor, Maria E., Alshawa, Anas, Hong, David S., Tsimberidou, Apostolia, Gong, Jing, Stephen, Bettzy, Subbiah, Vivek, Piha-Paul, Sarina A., Fu, Siqing, Sharma, Padmanee, Mendoza, Tito, Patel, Anisha, Thirumurthi, Selvi, Sheshadri, Ajay, Meric-Bernstam, Funda, Naing, Aung
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5962379/
https://ncbi.nlm.nih.gov/pubmed/29159766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0534-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller